Abstract: A material for an organic electroluminescence device which can be a cis-isomer or a trans-isomer of structural isomers, the content of the trans-isomer being more than that of the cis-isomer. The ratio (t/c) of the trans-isomer (t) and the cis-isomer (c) is preferably 2 or more.

Abstract: This invention is directed to acetylenic compounds as inhibitors of a nicotinamide adenine dinucleotide oxidase hydride donor useful in treating or ameliorating a reactive oxygen species mediated inflammatory disorder.

Abstract: The invention provides a process for the simultaneous preparation of 4,4?-diphenylmethanediamine and also diphenylmethane diisocyanate and polyphenylenepolymethylene polyisocyanates, which comprises the steps a) preparation of a mixture of diphenylmethanediamine and polyphenylenepolymethylenepolyamines by acid condensation of aniline and formaldehyde and sub-sequent work-up of the mixture, b) splitting-off of part of the mixture prepared in step a), c) distillation of the mixture separated off in step b) in a column, d) recirculation of the bottom product from step c) to the end product from step a) and condensation of the overhead product from step c), e) distillation of the overhead product from step c) in a column, f) recirculation of the overhead product from step e) to the end product from step a), g) isolation of the 4,4?-diphenylmethanediamine obtained as bottom product in step e), h) reaction of the mixture from step a) with phosgene and subsequent work-up of the reaction product.

Abstract: This invention provides compositions which comprise at least one aromatic secondary diamine having a Gardner color number no more than about 6. The aromatic secondary diamine either is in the form of one benzene ring having two secondary amino groups on the ring, or is in the form of two benzene rings connected by an alkylene bridge and having one secondary amino group on each ring. At least one N,N?-dihydrocarbylhydroxylamine is optionally present in the composition. Processes for producing such compositions are also provided.

Abstract: The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one heterocyclic nitric oxide donor group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension and (n) treating ophthalmic disorders. The cardiovascular compounds are preferably ?-adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors, anti-hyperlipidemic compounds, and antithrombotic and vasodilator compounds.

Abstract: Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of cancer. In particular, honokiol derivatives, pharmaceutical compositions comprising the derivatives, and methods for their use in the treatment of myeloma are provided.

Abstract: A new process for the preparation and purification of 4-4?-diamino-diphenyl-sulfone (dapsone) is described. The process described is a three step process comprising a condensation reaction with the synthesis of a thioeter intermediate and then steps of oxidation and reduction in suitable conditions in order to obtain a product with good yield and purity.

Abstract: The present invention relates to a compound of formula (I) wherein R1 is a radical of formula (II) R2 is —NH2 or a radical of formula (II), R3 and R4 are each independently of the other hydrogen, hydroxy, —NH2 or a radical of formula (II), R5 is hydrogen, halogen or —X—(CH2)n—Y, wherein X is a direct bond, —O— or —S—, Y is —OH or —OSO3H and n is a number from 0 to 6, with the proviso that at least one of the radicals R3, R4 and R5 is not hydrogen, to a process for the preparation thereof and to the use thereof in a method of producing mass-coloured plastics or polymeric colour particles.

Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

Abstract: A method of producing a first ethynyl compound represented by the following formula (1), the method including reacting a second ethynyl compound represented by the following formula (2) in a liquid phase in the presence of a reducing agent to obtain the first ethynyl compound, wherein Q1 represents an organic group; R1 and R2 each independently represent a hydrogen atom or a hydrocarbon group; and R1 and R2 may be bonded to each other.

Abstract: An electrophotographic photoreceptor comprising laminating a monolayer type photosensitive layer containing a charge generation material and a charge transport material or a laminate type photosensitive layer obtained by laminating a charge generation layer containing a charge generation material and a charge transport layer containing a charge transport material in this order, on a conductive support, wherein the charge transport layer of the monolayer type photosensitive layer or laminate type photosensitive layer contains an enamine compound represented by the following formula (1).

Abstract: The present invention relates to a process for further processing of the carbon-containing residue derived from fullerene production and from carbon-nanostructures production, characterized in that the residue is functionalized via introduction of chemical substituents, and the functionalization is carried out during or after the production process. The functionalized carbon-containing residue obtainable by the process is also provided, as is its use as a hydroxylating agent, wetting agent, additive in rubber compounds, and for tether-directed remote functionalization.

Abstract: A diamine includes a structure of formula (I), wherein X and Y are independently a divalence group selected from the group consisting of: —O—, —(C?O)—O—, —O—(C?O)—, —(C?O)—NH—, and —NH—(C?O)—; and R has a structure of formula (II): wherein R1, R2, R3, R4, R5, m, and n are as defined in Claim 1. A polyamic acid is prepared by reacting a diamine reactant including the aforesaid diamine of formula (I) with a tetracarboxylic dianhydride reactant. A liquid crystal orienting film contains a polyimide converted from the aforesaid polyamic acid.

Abstract: The invention relates to new compounds, namely capsaicin derivates, a new method for their production, and their use as micro-organism-repellent agents in paints and coatings, in particular for marine installations and ships, but also for land-based structures.

Abstract: The invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula (I).

Abstract: Process for preparing o-, m- or p-xylylenediamine by hydrogenation of o-, m- or p-phthalonitrile in the presence of a heterogenous catalyst, which comprises feeding a solution of the phthalonitrile in the corresponding isomer of crude xylylenediamine into the hydrogenation reactor, with the crude xylylenediamine having a purity in the range from 85 to 99.7% by weight and a content of higher boilers in the range from 0.3 to 15% by weight.

Abstract: The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scler

Abstract: The present invention discloses processes for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates.

Abstract: Methods for preparing an oligomer exhibiting supramolecular extension of ?-conjugation are described. The manipulation of intra-oligomeric properties such as ?-conjugation length and the precise architecture(s) resulting from inter-oligomeric variations resulting from supramolecular chemistry offers great promise in the design of nanoscale devices. As shown, self-assembly of the supramolecular structure can be induced by causing a molecule: dopant molar ratio to go beyond the predicted theoretical fully-doped molar ratio.

Abstract: A dendrimer according to example embodiments may include a triphenylamine core, wherein a conjugated dendron having no heteroatoms is coupled to the triphenylamine core. An organic memory device according to example embodiments may include an organic active layer between a first electrode and a second electrode, wherein the organic active layer includes the dendrimer according to example embodiments. A barrier layer may be provided between the first and second electrodes. A method of manufacturing the organic memory device according to example embodiments may include forming an organic active layer between a first electrode and a second electrode, the organic active layer including the dendrimer according to example embodiments.

Abstract: A process for the production of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula II wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of Formula I are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase II.

Abstract: A polyol monomer comprising the formula: R1 and R3 are —H, aliphatic, aromatic, or ether; R2 is aliphatic, aromatic, ester, ether, or acrylic, and R1 contains a hydroxyl group, R3 contains a hydroxyl group, R2 contains —O—CH2—CH(OH)—, or any combination thereof. The polyol monomer may be made by reacting an epoxy and an amine. Either the epoxy contains more than one epoxide groups, the amine contains a hydroxyl group, or both. A thermoset made by reacting the polyol monomer with a polyisocyanate.

Abstract: The subject of the present invention is to provide a method for deuteration, which can obtain a compound having an aromatic ring and/or a heterocyclic ring at an improved deuteration ratio. The present invention relates to a method for deuteration of a compound having an aromatic ring and/or a heterocyclic ring, comprising reacting the compound having an aromatic ring and/or a heterocyclic ring with a heavy hydrogen source in the presence of an activated mixed catalyst of not less than two kinds of catalysts selected from among a palladium catalyst, a platinum catalyst, a rhodium catalyst, an iridium catalyst, a ruthenium catalyst, a nickel catalyst and a cobalt catalyst.

Abstract: Disclosed are efficient methods for loading amino derivatives onto trityl chloride resins and for cleaving chemically modified amino derivatives from trityl chloride resins. Methods for making a library of discrete chemically modified amino derivatives also disclosed.

Abstract: An optionally substituted oligomer or polymer comprising a repeat unit of formula (I); wherein each Ar1 and Ar3 is the same or different and independently represents an optionally substituted aryl or heteroaryl; n is at least 1; Ar2 represents an optionally substituted aryl or heteroaryl comprising a linking ring to which the two nitrogen atoms are both directly linked; and at least one of Ar2 and either or both of Ar1 is substituted with at least one substituent.

Abstract: Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.

Abstract: Polyionic liquid salts are provided comprising polycationic or polyanionic molecules. Further provided are solvents comprising one or more polyionic liquid salts, and the use of such polyionic liquid salts as stationary phases in gas chromatography, and as a reagent in electrospray ionization-mass spectrometry (ESI-MS).

Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Abstract: Compounds of the formula (I) wherein R is phenyl, or phenyl substituted by Cl, Br, C1-C4alkyl or CF3; R1 is H or methyl or ethyl; R2 is H or methyl or acyl; R3 is H or methyl; R?4 is —CH3 or ?CH2; may be obtained in high enantiopurity by hydrogenation of a compound of the formula (II) wherein R and R3 are as in formula (I); A is acyl; and R4 is —CH3 or ?CH2; in the presence of a chiral Rhodium or Ruthenium catalyst. Residues R1 as methyl or ethyl and/or R2 as H or methyl may subsequently be introduced without racemization by deacylation and optional alkylation.

Abstract: Processes comprising: providing an aromatic alcohol; and reacting the aromatic alcohol with ammonia at a temperature of 80 to 350° C. in the presence of hydrogen and a heterogeneous catalyst to form a crude reaction product comprising a corresponding primary aromatic amine, wherein the heterogeneous catalyst comprises a catalytically active composition which, prior to reduction with hydrogen, comprises 90 to 99.8% by weight of zirconium dioxide (ZrO2), 0.1 to 5.0% by weight of an oxygen-comprising compound of palladium, and 0.1 to 5.0% by weight of an oxygen-comprising compound of platinum.

Abstract: Selective estrogen receptor modulators, as well their related pharmaceutical compositions and methods of use, are provided herein. These estrogen receptor modulators include compounds that primarily exhibit estrogen receptor antagonist activity or primarily exhibit selective estrogen receptor antagonist and agonist activity, i.e., SERM activity, in specific tissue types. Particular embodiments provide compounds that behave as NeuroSERMs promoting neurotrophism and neuroprotection in brain tissue. These NeuroSERMs represent a subset of the modulators compounds provided herein that can cross the blood-brain-barrier and exert estrogen receptor agonist-like effects in the brain. The compounds should be useful for treating a variety of diseases, particularly estrogen receptor-mediated diseases and disorders, such as osteoporosis, breast and endometrial cancers, atherosclerosis and Alzheimer's disease.

Abstract: The present invention relates to iminecalixarene derivatives, iminecalixarene derivative monolayers prepared as a monolayer on a solid substrate by using said iminecalixarene derivatives, a protein chip substrate prepared by fixing all kinds of proteins on a chip substrate in a solution phase without any treatment, while ammonium groups on the surface of the proteins are irreversibly recognized by said iminecalixarene derivative monolayer, and protein chips prepared by using the protein fixation on said substrate.

Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

Abstract: The invention provides novel N-benzyl-N-propargyl-amines that are monoamine oxidase inhibitors, but generally exhibit little or no CNS effects.

Abstract: A process for the preparation of 4-hydroxyalkylamino-2-nitro-anisoles of the general formula (I) wherein m is 2 or 3; by reaction of a 4-halogeno-3-nitro-aniline of formula (II) with a chloroalkyl-chloroformate of formula (III), alkaline ring closure of the resulting carbamate and nucleophilic replacement of the halogeno atom by a methoxy group to form a derivative of formula (IV), and finally ring opening of the resulting cyclic carbamate by treatment with methanolic alkali metal hydroxide, followed by neutralization with inorganic or organic acids, wherein the complete reaction is executed in a non-aqueous medium; as well as process for the preparation of 2-amino-4-hydroxyalkylamino-anisoles of formula (V)

Abstract: To provide an organic electroluminescent device showing various luminescent color tones and having high heat resistance, a long lifetime, high emission luminance, and high emission efficiency, in particular, an organic electroluminescent device capable of preventing the attenuation of emission luminance in association with the driving of the device. Provided is an organic electroluminescent device including: an aromatic amine compound having a specific structure; a cathode; an anode; and one or multiple organic thin film layers having at least a light-emitting layer, the one or multiple organic thin film layers being interposed between the cathode and the anode, in which at least one layer of the one or multiple organic thin film layers contains the aromatic amine compound alone or as a component of a mixture.

Abstract: The present invention relates to a method for producing an unsaturated aliphatic primary amine including subjecting an unsaturated aliphatic nitrile having 16 to 22 carbon atoms to hydrogen reduction in the presence of ammonia using a hydrogenation catalyst to produce an unsaturated aliphatic primary amine, wherein 0.01 parts by weight to 1.0 part by weight of aromatic carboxylic acid amide is added based on 100 parts by weight of the unsaturated aliphatic nitrile, and a partial pressure ratio of ammonia to hydrogen is adjusted to 8/2 to 6/4. The present invention also relates to an unsaturated aliphatic primary amine, which is produced by the production method.

Abstract: Benzamidine derivatives of the following formulae or analogs thereof, i.e., pharmaceutically acceptable salts thereof, are provided.

Abstract: A process for preparing a 3-aminophenylacetylene compound of formula (5), including: a) reacting a 3-haloaniline compound of formula (1) with an acetylene compound of formula (2) in the presence of a palladium compound, a copper compound, and an amine compound of formula (3) to form an aniline compound of formula (4); b) precipitating the aniline compound of formula (4) in the form of a crystal, and isolating it by solid/liquid separation; and c) reacting the aniline compound of formula (4) with a base to obtain 3-aminophenylacetylene.

Abstract: The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications.

Abstract: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3? kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.

Abstract: Process for preparing alkylated amines The present invention relates to a process for preparing a compound of the formula (I) by reacting a compound of the formula (II) with a compound of the formula (III) (RO)2CO (III) or a compound of the formula (IV) in the presence of a zeolite of the NaY faujasite type, where Ar, X, R and n are each as defined in claim 1.

Abstract: A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)-propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the presence of an optically active catalyst to reduce 1-indanones. The chiral product, either (S)- or (R)-indanols undergo nucleophilic substitution to produce the named product. In an additional aspect, the invention relates to novel intermediates and compounds, namely, substituted indanones, substituted (S)-indanols and substituted (R)-indanols.

Abstract: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.

Abstract: A single-step process is disclosed for the ring alkylation of at least one N-alkyl-N?-phenyl-phenylenediamine with at least one olefin wherein the process comprises heating a mixture of the N-alkyl-N?-phenyl-phenylenediamine(s) and olefin(s) in the presence of a catalytic amount of at least one alkyl aluminum halide at a temperature of from about 50 to about 350° C. in a sealed vessel for from about one to about 30 hours.

Abstract: The present application is directed to compounds that are the reaction product of (i) a hydrocarbyl phenol, (ii) a hindered phenol; (iii) an diaryldiamine and (iv) an aldehyde. Methods of making and using the compounds of the present application are disclosed.

Abstract: The present invention is directed to benzylether and benzylamino derivative compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Abstract: Cyclohexylurea compounds corresponding to formula I a method for producing them, pharmaceutical compositions containing them, and the use of such compounds as pharmaceutically active agents with nociceptin/ORL1 receptor system activity for treating pain or other conditions associated with the nociceptin/ORL1 receptor system.